Ourania Tatsis - 09 Aug 2022 Form 4 Insider Report for VERTEX PHARMACEUTICALS INC / MA (VRTX)

Signature
/s/ Joy Liu, Attorney-in-Fact
Issuer symbol
VRTX
Transactions as of
09 Aug 2022
Net transactions value
-$418,557
Form type
4
Filing time
10 Aug 2022, 16:06:08 UTC
Previous filing
21 Mar 2022
Next filing
03 Feb 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VRTX Common Stock Sale $86,882 -292 -0.61% $297.54 47,198 09 Aug 2022 Direct F1, F2, F3, F4
transaction VRTX Common Stock Sale $202,865 -679 -1.4% $298.77 46,519 09 Aug 2022 Direct F2, F3, F5
transaction VRTX Common Stock Sale $84,841 -283 -0.61% $299.79 46,236 09 Aug 2022 Direct F2, F3, F6
transaction VRTX Common Stock Sale $21,646 -72 -0.16% $300.64 46,164 09 Aug 2022 Direct F2
transaction VRTX Common Stock Sale $22,324 -74 -0.16% $301.67 46,090 09 Aug 2022 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 134 shares previously purchased under the issuer's Employee Stock Purchase Plan.
F2 Transaction made pursuant to Ms. Tatsis' company approved trading plan under Rule 10b5-1.
F3 Ms. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F4 Open market sales reported on this line occurred at a weighted average price of $297.54 (range $297.00 to $297.80).
F5 Open market sales reported on this line occurred at a weighted average price of $298.77 (range $298.29 to $299.19).
F6 Open market sales reported on this line occurred at a weighted average price of $299.79 (range $299.44 to $300.33).